403 related articles for article (PubMed ID: 30506897)
1. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
3. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
4. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
5. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
7. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
[TBL] [Abstract][Full Text] [Related]
8. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
11. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
[TBL] [Abstract][Full Text] [Related]
12. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
[TBL] [Abstract][Full Text] [Related]
14. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
16. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
17. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
18. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]